natgillin/translations-raw huggingface dataset:
providing an aminooxy compound comprising a second reactive group, wherein the aminooxy compound is chosen from compounds of Formula III: 
(b) osiguravanje aminooksi spoja koji sadrži aminooksi skupinu i drugu reaktivnu skupinu, pri čemu je aminooksi spoj odabran od spojeva s Formulom III:
The acidity of the gastric juice samples are determined by titration to pH 7.0, and the acid output calculated. 
Kisclost uzoraka želučanog soka je određena titracijom kod pH 7.0, a količina kiseline je izračunata.
The AvPAL variant of claim 1, wherein the cysteine residues at positions 503 and 565 of AvPAL have been substituted by a serine residue (SEQ ID NO:11). 
AvPAL varijanta u skladu s patentnim zahtjevom 1, naznačena time, da su cisteinski ostaci na položajima 503 i 565 AvPAL-a supstituirani serinskim ostatkom (SEQ ID NO:11).
Compound 1 for use in the treatment of diabetes, wherein the compound is administered once weekly or less frequently and, on average, during a period of time of at least 1 month, 6 months or 1 year, said compound is not administered more frequently to the same patient. 
Spoj prema patentnom zahtjevu 1, za uporabu u liječenju dijabetesa, naznačeno time da je spoj primjenjen jednom tjedno, ili rjeđe, 1, u prosjeku, tijekom vremenskog perioda od najmanje 1 mjeseca, 6 mjeseci ili 1 godine, navedeni spoj nije primjenjen češće na istog pacijenta.
The transgenic mouse of claim 1, wherein the endogenous λ light chain immunoglobulin locus comprises the endogenous mouse enhancer 2.4. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što endogeni lokus imunoglobulina lakog lanca 2 sadrži endogeni mišji pojačivač 2.4 ili endogeni mišji 3' pojačivač.
In one embodiment, the recombinant protein is a blood clotting factor. In another embodiment, the blood clotting factor is selected from the group consisting of Factor II, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, von Willebrand Factor, Factor XII and Factor XIII. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se rekombinantni čimbenik zgrušavanja krvi bira iz skupine koju čino Čimbenik TI, Čimbenik V, Čimbenik VIL, Čimbenik VIII, Čimbenik IX, Čimbenik X, Čimbenik XI, von Willebrandov čimbenik, Čimbenik XII i Čimbenik XIII.
The resulting solution was stirred for 45 min then the volatiles evaporated to give the title compound (192 mg, 100%) as a yellow solid which was a mixture of diastereomers. 
Dobivenu otopinu miješa se 45 minuta, a zatim se hlapive tvari otpari kako bi se dobilo naslovni spoj (192 mg, 100 %) u obliku žute krutine, koja je smjesa dijastereomera.
The method of claim 10 or 11, wherein the recombinant eukaryotic host cell is a HEK293 cell, HEK293T cell, a CHO cell or a lymphocytic cell. 
Metoda sukladno patentnom zahtjevu 10 ili 11, naznačeno time da rekombinantna eukariotska stanica je HEK293 stanica, HEK293T stanica, CHO stanica ili limfocitna stanica.
The method of claim 1, wherein said dsRNA duplex has a length of from 8 base pairs (bp) to 30 bp. 
(1i) duljinu od 8 parova baza (bp) do 30 bp; ili (ili) duljinu od 15 parovi baza (bp) do 15 bp.
The universal and rapid covering system according to claim 1, wherein said sleeve (15) is constituted of material made of fabric or of a series of rings (30) connected to each other and spaced with ropes (31, 32). 
Univerzalan 1 brz sustav prekrivanja prema zahtjevu 1, pri čemu je navedena navlaka (15) sačinjena od tkanine ili niza prstenja (30) međusobno povezanih i razmaknutih putem užadi (31, 32).
The method of claim 1 or claim 2, wherein said first solid support and second solid support each is independently selected from the group consisting of a polymer bead, an agarose bead, a polystyrene bead, an acrylamide bead, a solid core bead, a porous bead, a paramagnetic bead, glass bead, controlled pore bead, a microtitre well, a cyclo-olefin copolymer substrate, a membrane, a plastic substrate, nylon, a Langmuir-Blodgett film, glass, a germanium substrate, a silicon substrate, a silicon wafer chip, a flow through chip, a microbead, a nanoparticle, a polytetrafluoroethylene substrate, a polystyrene substrate, a gallium arsenide substrate, a gold substrate, and a silver substrate. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da je svaki od navedenog prvog čvrstog nosača i navedenog drugog čvrstog nosača, neovisno odabran iz skupine koju čine: polimerna kuglica, agarozna kuglica, polistirenska kuglica, akrilamidna kuglica, kuglica s krutom jezgrom, porozna kuglica, paramagnetska kuglica, staklena kuglica, kuglica s kontroliranim porama, mikrotiter s otvorima, supstrat cikloolefin-kopolimera, membrana, plastični supstrat, najlon, Langmuir-Blodgett-sloj, staklo, germanijev supstrat, silicijev supstrat, tanki silikonski pločasti čip, protočni čip, mikrokuglica, nanočestica, supstrat politetrafluoroetilena, supstrat polistirena, supstrat galijarsenida, zlatni supstrat i srebrni supstrat.
A polymer composition comprising polymer and at least 3 wt. % of a functional filler, wherein the polymer comprises from 90 to 100 % by weight of a mixture of polyethylene and polypropylene, and wherein the functional filler comprises (i) an inorganic particulate and (ii) a coating comprising a first compound including a terminating propanoic group or ethylenic group with one or two adjacent carbonyl groups. 
anorganski partikulat; i oblogu, koja sadrži prvi spoj, koji sadrži krajnju propanskokiselinsku skupinu ili etilensku skupinu, uz jednu ili dvije susjedne karbonilne skupine; i miješanju otpadnog polimera s funkcionalnim punilom kako bi se dobilo reciklirani polimer, gdje funkcionalno punilo dolazi u količini jednakoj ili većoj od 10%, težinski, otpadnog polimera.
A key as defined in claim 11, wherein said side code recesses form concavities with lower bottom portions located at a number of different levels, each representing a code. 
Ključ kako je definiran u zahtjevu 11, naznačen time da navedena bočna kodna udubljenja tvore konkavnosti s nižim donjim dijelovima smještenim na većem broju različitih razina, od kojih svaka predstavlja kod.
It is expressed in tissues in inflammation or stress conditions. 
Eksprimira se u tkivu pri upalnim ili stresnim uvjetima.
In DE 4129528 and EP 357128 the reactive diluents consist of fatty acid esters of various unsaturated alkyl ether alcohols. 
U DE 4129528 i EP 357128 reaktivna sredstva za razrjeđivanje sastoje se od estera masnih kiselina s raznim nezasićenim alkil eter alkoholima.
determining the synchronization dependent on the likelihood measure. A computer program adapted to perform the method according to claim 16 or claim 17, when the computer program runs on a computer. 
Računalni program, naznačen time, da je prilagođen za izvršavanje postupka prema zahtjevu 16 ili zahtjevu 17, kada se taj računalni program pokreće na računalu.
13: Competition ELISA of the pre-candidate pool antibodies with the parental antibody 2A10. 
Slika 11: Kompelticijska ELISA protutijela iz fonda predkandidata s roditeljskim protutijelom 2A 10.
A feed conveyor 92, located at an upper end of the conveyor 52, and secured to the support frame 50 in any suitable manner serves to distribute the material to be dried across the vertical path between the belts 54, 56 . 
Sušilica prema patentnom zahtjevu 1, još obuhvata dovodni transporter (92) postavljen na gornjem kraju sredstva za transport za prijem materijala koji treba osušiti i raspodjelu materijala preko vrha vertikalne putanje.
processing membrane of sturgeon roe sacks following roe extraction to obtain a liquid mixture; 
obradu membrane jajnika jesetre poslije ekstrahiranja ikre da se dobije tekuća smjesa;
The oral composition of any one of claims 1-9, wherein the composition further comprises 
Oralni sastav iz bilo kojeg od patentnih zahtjeva 1-9, pri čemu sastav nadalje sadrži
The method of Embodiment 1, wherein atomizing the lubricating oil comprises passing the lubricating oil and the refrigerant through a metal mesh. 
Postupak prema Zahtjevu 1, gdje atomiziranje ulja za podmazivanje podrazumijeva propuštanje ulja za podmazivanje i rashladnog sredstva kroz metalnu mrežu.
The method of claims 5 or 6, wherein the genotype of the E. coli lacks degP and prc genes and harbors a mutant spr gene. 
Postupak prema zahtjevima 5 ili 6, naznačen time, da genotipu bakterije E. coli nedostaju geni degP i prc, ali uzgaja mutirajući gen spr.
Each of the above-defined "C1-9 alkyl group" for the below-defined 4) of group B, and the above-defined "C1-4 alkyl group" for RB1 to RB31 is optionally substituted by the same or different 1 to 3 substituents selected from group A. 
R', RŽi R* su isti ili različiti i svaki je Ci alkilna skupina, C, alkinilna skupina, gdje su Ci alkilna skupina i C24 alkenilna skupina izborno supstituirane s 1 do 3 supstituenta, koje se bira iz sljedeće skupine A, ili
Asenapine maleate (260 g) as prepared according to example 1 was dissolved in a mixture of ethanol (480 ml) and water (50 ml) by heating to 57 °C. 
Asenapin maleat (260 g) dobiven prema primjeru 1 otopljen je u smjesi etanola (480 ml) i vode (50 ml) grijanjem na 57 %C.
A method for producing a compound of general structure I, 
Postupak proizvodnje spoja općenite strukture I,
In a preferred embodiment, the transmitter generates signals in a cyclical fashion, i.e. generating sequential signals that represent the state of each switch, and continuously repeating this sequence of signals. 
U poželjnoj izvedbi, odašiljač ciklički generira signale, to jest, generira slijed signale koji predstavljaju stanje svake od sklopki, te neprekidno ponavlja sekvencu signala,
R3023 (SEQ ID NO: 104) binding was not detected at the highest concentration tested. 
Polipeptid u skladu s patentnim zahtjevom 1, pri čemu je navedeni polipeptid SEQ ID NO: 184.
To a heterogeneous solution of magnesium (0.771 g, 0.032 mole) in THF ((10 mL) under nitrogen atmosphere are added few crystals of iodine, followed by 5 mL of 1-bromo-4-nonylbenzene (6.5 g, 0.0229 mole) in THF (40 mL) with vigorous stirring at 65 °C. After initiation, rest of the solution of 1-bromo-4-nonylbenzene is added dropwise to the reaction mixture and heated under reflux for 1 h. 
CHO U heterogenu otopinu magnezija (0,771 g, 0,032 mol) u THF-u ((10 ml) u atmosferi dušika doda se nekoliko kristala joda, a zatim 5 ml 1-brom-4-nonilbenzena (6,5 g, 0,0229 mol) u THF-u (40 ml), uz snažno miješanje na 65 *C. Nakon početka u reakcijsku smjesu se ukapa statak otopine 1-brom-4-nonilbenzena, te grije 1 sat na refluksu.
The compound according to Claim 1, wherein R1 is a direct-bonded unsaturated 5-, 6- or 7-membered monocyclic ring containing 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more than one O or S, wherein the ring is substituted by 1 R2 substituents selected from halo, nitro, cyano, C1-4alkyl, OC1-4alkyl, OC1-4haloalkyl, NHC1-4alkyl, N(C1-4alkyl)C1-4alkyl and C1-4haloalkyl. 
Spoj prema patentnom zahtjevu 1, naznačen time što R1 je direktno vezani ili kisikom vezani zasićeni, djelomično zasićeni ili nezasićeni 5-, 6- ili 7-člani monociklični prsten koji sadrži 1, 2, 3 ili 4 atoma izabrana od N, O i S, ali koji ne sadrži više od jednog O ili S, pri čemu su dostupni atomi ugljika u prstenu supstituirani sa 0, 1 ili 2 okso ili tiokso grupe, gdje je prsten supstituiran sa 0 ili 1 R2 supstituentom, i prsten je dodatno supstituiran sa 0, 1, 2 ili 3 supstituenta nezavisno izabrana od halo, nitro, cijano, C1-4alkil, OC1-4alkil, OC1-4haloalkil, NHC1-4alkil, N(C1-4alkil)C1-4alkil i C1-4haloalkil.
The invention also provides: 
Izum također osigurava:
The fuel element according to the present invention and its use in smoking articles is described in greater detail in the accompanying drawings and in the detailed description of the invention which follow. 
Cigaretni substitut iz sadašnjeg izuma opisan je detaljnije na pratećim crtežima 1 u detaljnijem opisu izuma koji slijedi. Slike 1 do 9
The IL-23 antagonist for use according to Claim 50, wherein the IL-23 antagonist is a monoclonal antibody or a monoclonal antibody fragment that binds to and inhibits the activity of IL-23p19 or IL-23R. 
1L-23 antagonist za uporabu u skladu sa zahtjevom 50, naznačen time, da IL-23 antagonist je monoklonsko antitijelo ili fragment monoklonskog antitijela koje se veže na i inhibira djelovanje IL-23p19 ili IL-23R.
The method according to claim 1, wherein said monocarboxylic acid is a concentrated acid more than about 90% by weight. 
Pripravak prema zahtjevu 4 ili 5, naznačen time što je ta monokarboksilna kiselina koncentrirana kiselina više od 90%, poželjnije 99% ili više.
A compound as defined in claim 1 or a pharmaceutically acceptable salt, stereoisomer and/or solvate thereof for use in therapy. 
CO E £S -\] ao (IIBa) ili njegova farmaceutski prihvatljiva sol, solvat, i/ili ester.
actuating an inhaler comprising a spray nozzle unit and a cartridge containing the aqueous solution and administering the aqueous solution to a patient in the form of droplets having a mass median aerodynamic diameter of from 4 to 8 µm. 
Vodena otopina za uporabu sukladno patentnom zahtjevu 7-12 pri čemu isporuka pacijentu, sadrži: pokretanje inhalatora koji sadrži jedinicu s mlaznicom za raspršivanje i patronu koja sadrži vodenu otopinu i davanje vodene otopine pacijentu u obliku kapiljica koje imaju srednju aerodinamičku masu promjera od 4 do 8 um.
Top wall of the capsule 18 
gornja stijenka čahure 18
The method of claim 5, wherein the mammalian cells are CHO cells. The method of claim 6, wherein the mammalian cells are CHO cells. The method of claim 1, wherein culturing the one or more mammalian cells comprises continuous cultivation of the mammalian cells. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što su jedna ili više stanica stanice sisavca, po mogućnosti CHO stanice. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se uzgoj jedne ili više stanica sastoji u:
A method for recycling a mixture of polymethylmethacrylate (PMMA) and/or acrylonitrile-butadiene-styrene (ABS) and crosslinked polymethylmethacrylate, characterised by passing said mixture under pressure through at least three spaced-apart filters in series, in such a manner as to reduce the size of the crosslinked PMMA particles present in the mixture to below 200 micron. 
Postupak za recikliranje mješavine polimetilmetakrilata (PMMA) i/ili akrilonitril-butadien-stirena i umreženog polimetilmetakrilata, naznačen time što navedena mješavina prolazi pod pritiskom kroz najmanje tri filtra koji su postavljeni u seriju i razmaknuti su jedan od drugoga, i to radi toga da se smanji veličina čestica umreženih PMMA, koje čestice su prisutne u mješavini, ispod 200 mikrona.
a processor (210) configured to: receive a transmission signal, retrieve, from the storage unit, position information matching a type of data symbol of the transmission signal from among the stored position information, and 
primanje prijenosnog signala, preuzimanje, iz memorije, pozicijskih informacija koje odgovaraju vrsti simbola podataka prijenosnog signala između pohranjenih pozicijskih informacija, i oporavak podatkovnog simbola iz prijenosnog signala temeljem dohvaćenih podataka o položaju.
emission means (6, 7, 8, 9) for emitting infrared radiation, to dry out the walls and / or objects contained in the room, the emission means comprising: 
- sredstva za emisiju (6, 7, 8, 9) za emisiju infracrvenog zračenja, kako bi se osušilo zidove 1 / ili predmete u prostoriji, sredstva za emisiju obuhvaćaju:
The method of E 20, further comprising administering the IL-23 antagonist during a third treatment period that begins upon the end of the second treatment period. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 20, naznačen time, da navedeno liječenje nadalje obuhvaća primjenu IL-23 antagonista za vrijeme trećeg razdoblja liječenja koje započinje završetkom drugog razdoblja liječenja.
The process according to claim 1 wherein the compounds of Formula XX is selected from: 
Postupak u skladu s patentnim zahtjevom 13, naznačen time, da su spojevi Formule XX odabrani među sljedećim spojevima:
A radiation curable gel nail coating composition according to aspect 6, wherein the plasticizer is selected from sucrose acetate isobutyrate, ethyl tosylamide, and camphor, or a mixture thereof. 
Pripravak u vidu gel-laka za nokte za čije sušenje se korisiti zračenje prema patentnom zahtjevu 6, naznačen time, što je plastifikator izabran iz grupe koju čine acetat izobutirat saharoza, etil tozilamid, kamfor i njihove smjese.
In various embodiments, the non-human animal is a rodent, and the human portions of the chimeric human/rodent MHC II a and B polypeptides comprise human sequences derived from HLA class II protein selected from the group consisting of HLA-DR, HLA-DQ, and HLA-DP. 
1 genski lanac HLA-DP a i/ili ljudski dio kimernog MHC II f polipeptida čovjeka/glodavca kodira ljudski genski lanac klase HLA II a koji je odabran iz grupe koja sadrži genski lanac HLA-DR (8, genski lanac HLA-DQ fi i genski lanac HLA-DP (.
In one embodiment of the present invention, the substrate comprises one or more formulations of the mineral composition, said formulation being selected from the group consisting of a coating composition, filler, surface filling, and a mineral slurry or mixtures thereof. 
Podloga prema zahtjevu 4 naznačena time što sadrži jednu ili više formulacija pripravka kalcijevog karbonata, navedena formulacija je odabrana iz skupine koja sadrži pripravak za oblaganje, punilo, površinsko punjenje, te suspenziju kalcijevog karbonata ili njihove smjese.
Embodiments of formulations according to this invention have impurity content that is significantly reduced with respect to that of conventional formulations. 
Varijante oblika prema ovom izumu imaju sadržaj nečistoća koji je značajno smanjen u odnosu na taj sadržaj kod uobičajenih oblika.
is selected from Leu and Lys; and/or 
X27 je odabran od Leu i Lys; i/ili
the compound is a diester, especially a C1-6 alkyl diester, more especially a C 1-3 alkyl diester, particularly a diethyl ester. 
Spoj je diester, posebno C,.3 alki diester, bolje C,.3 alkil dioster.
a second active selected from osmotic agents, ENaC blockers, anti-inflammatory agents, bronchodilatory agents, antihistamine agents, anti-tussive agents, antibiotic agents and DNase drug substances, wherein the first and second actives may be in the same or different pharmaceutical composition. A method for the symptomatic treatment of cystic fibrosis, asthma, or COPD, comprising: 
Farmaceutska kombinacija, naznačena time, da obuhvaća: prvi djelatni sastojak koji sadrži spoj ili njegovu farmaceutski prihvatljivu sol, prema bilo kojem od zahtjeva 1 do drugi djelatni sastojak odabran od sljedećih: osmotska sredstva, ENaC-blokatori, protuupalna sredstva, bronhodilatorna sredstva, antihistaminska sredstva, antitusivna sredstva, antibiotici i ljekovite DNase-supstance, pri čemu prvi i drugi djelatni sastojci mogu biti u istom ili u drugačijem farmaceutskom sastavu.
Methods: A similar experiment approach was used in both cat and mouse studies. 
Metode: Sličan je eksperimentalni pristup korišten i u studijama na mačkama i na miševima.
The present patent application is the divisional patent application of the parent patent application (EP 11007823 A1). 
Broj objave europske prijave patenta: EP 2598501 A1 Datum objave europske prijave patenta:
A nucleic acid encoding the immunoadjuvant compound according to any one of claims 1 to 9. 
Nukleinska kiselina, naznačena time što kodira imunoadjuvantni spoj u skladu s bilo koji od patentnih zahtjeva 1 do 9.
The back support device and safety bow set according to claim 1, wherein the back support device is depth adjustable. The back support device and safety bow set according to claim 1, wherein the arms are molded or fixed on the rear side of the back support device with a distance from side edges of the back support device. 
Sredstvo za naslanjanje prema bilo kojem od prethodnih zahtjeva, naznačeno time, da su ručice (83, 93) izlijevane ili učvršćene na stražnjoj strani samog sredstva za naslanjanje (80, 90) sa udaljenošću od bočnih rubova, tako da presvlaka može biti prevučena preko rubova samog sredstva za naslanjanje.
The combined organic phases were evaporated and the residue subjected to purification using Biotage Flash-75 chromatography apparatus (2 kg silica gel), eluting with dichloromethane and increasing proportions of ether to give the title compound (D3) (34.5 g, 72%) as a pale brown solid; 
Pomiješane organske faze se otpari, a ostatak podvrgne pročišćavanju uređajem za kromatografiju Biotage Flash-75 (2 kg silikagcla), uz cluiranje diklormetanom, uz povećavanje udjela ctera kako bi se dobilo naslovni spoj (D3) (34,5 g, 72 %) u obliku blijedosmeđe krutine;
A compound according to embodiment 36 wherein R4 is phenyl substituted at the 4-position with hydroxy, C1-3alkylaminocarbonyl, or aminocarbonyl, and substituted at the 2- and 6- positions with methyl substituents. 
Spoj prema zahtjevu 32 naznačen time da R* je fenil supstituiran na 4-poziciji sa hidroksi, C,salkilaminokarbonil ili aminokarbonil i supstituiran na 2-poziciji i 6-poziciji sa metil supstituentima.
The chemical entity of claim 1, wherein: 
Kemijski entitet odabran od:
wherein the pressure medium source is a capsule (24) of the pressure medium under pressure, whereby the pressure medium is a gas, and 
Spremnik (1) u skladu s patentnim zahtjevom 6 ili 7, naznačen time što je izvor tlačnog medija kapsula (24) za tlačni medij pod tlakom, gdje je tlačmi medij plin.
Preferably, the covering layer includes a reinforcement layer, such as a woven mat, netting, mesh or the like, and preferably a fibre reinforced layer. 
Poželjno je da pokrovni sloj sadrži sloj ojačanja, kao što je tkani mat, mrežu od vlakana, plastičnu ili metalnu mrežu, ili nešto slično, i po mogućnosti sloj ojačan vlaknima.
On the contrary, if the star centers of the phase sub-modules 34 R, 34 S, 34 T are not connected to each other, if one of them switches off, or has a malfunction, a source of impulses is lost. 
Uređaj prema patentnom zahtjevu 1, naznačen time što je svaki od faznih pod-modula (34R, 34S, 34T) spojen sa zvjezdastim spojem i zvijezda je središte pojedinačnih pod-modula (34R, 34S, 34T) međusobno spojenih na nulu (N).
The sterile, injectable composition of claim 4, wherein the hyaluronic acid or the salt thereof has an average molecular weight ranging from 50,000 to 10,000,000 Daltons. 
Postupak prema patentnom zahtjevu 1, naznačen time što hijaluronska kiselina ima prosječnu molekularnu težinu u rasponu od 50 000 do 10 000 000 Daltona.
a semisubmersible platform comprising buoyancy mechanisms controllable to change buoyancy of the semisubmersible platform and having storage and maintenance facilities for supporting aquaculture, a framework separate from the semisubmersible platform and connected thereto, wherein the framework is submerged below sea level 
poluuronjive platforme (110) koja se pak sastoji od mehanizama koji rade na principu uzgona 1 pomoću kojih se može mijenjati uzgon poluuronjive platforme (110) te od potpornih objekata za skladištenje i održavanje akvakulture, -
A protein comprising an amino acid sequence of SEQ ID NOs. 145 or 146. 
sekvencu aminokiseline od jedne sekvence aminokiseline izabrane iz grupe koja se sastoji od SEQ ID BR: 142, 143 I 147-151.
These status monitoring signals 37 can be, for example, the temperatures of the thermoblocks, the flow-indicating signals from the flow meters, the pressure at the secondary side of the pumps as well as the water level in the water reservoirs 1, 2. 
Ti signali za praćenje stanja 37 mogu, primjerice, biti temperatura termoblokova, signali o protoku iz mjerača protoka, tlak na sekundarnoj strani pumpi, kao i razina vode u spremnicima za vodu 1 12.
After evaporation of the solvents under vacuum, the residue was purified by chromatography on silica gel (eluant: 3% to 4% 7N methanolic ammonia in dichloromethane) to give the title compound as a white solid (77 mg, 36%). 
Nakon otparivanja otapala pod vakuumom, talog je pročišćen kromatografijom na silika-gelu (eluens: 3% do 4% 7N metanolni amonijak u diklormetanu), čime je dobiven spoj iz naslova u obliku bijele krutine (77 mg, 36 %).